U.S. markets closed
  • S&P Futures

    4,666.00
    +15.00 (+0.32%)
     
  • Dow Futures

    35,219.00
    +142.00 (+0.40%)
     
  • Nasdaq Futures

    16,435.25
    +44.50 (+0.27%)
     
  • Russell 2000 Futures

    2,254.70
    +14.50 (+0.65%)
     
  • Crude Oil

    71.14
    +1.19 (+1.70%)
     
  • Gold

    1,787.30
    +2.10 (+0.12%)
     
  • Silver

    22.93
    +0.08 (+0.34%)
     
  • EUR/USD

    1.1296
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.5300
    +0.0480 (+3.24%)
     
  • Vix

    22.96
    -5.66 (-19.78%)
     
  • GBP/USD

    1.3316
    +0.0004 (+0.03%)
     
  • USD/JPY

    113.7770
    +0.1690 (+0.15%)
     
  • BTC-USD

    57,721.88
    -68.02 (-0.12%)
     
  • CMC Crypto 200

    1,454.65
    +25.72 (+1.80%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,639.24
    +355.32 (+1.26%)
     

China Biologic receives $4.59 bln take-private buyout offer

Sept 18 (Reuters) - China Biologic Products Holdings Inc said on Wednesday it had received a take-private deal for $4.59 billion in cash from a consortium of buyers.

Shares of the company, which develops plasma-based therapies and was listed on the Nasdaq in 2009, were up 7% after market.

The offer of $120 per share represents a premium of 16.3% to China Biologic's Wednesday close of $103.10.

The buyer group includes Beachhead Holdings Ltd, CITIC Capital China Partners IV LP, PW Medtech Group Ltd, Parfield International Ltd, HH Sum-XXII Holdings Ltd and V-Sciences Investments Pte Ltd. (https://reut.rs/2mnFvlQ)

In August 2018, China Biologic rejected a $3.9 billion offer from a consortium led by its former chief executive officer. (https://reut.rs/2BKMZXo) (Reporting by Bharath Manjesh in Bengaluru; Editing by Shounak Dasgupta)